{"text_format":"3","workbook":"xls","n_sheets":1,"sheets":["Additional Table 2"],"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"Additional Table 2","index":0,"n_rows":24,"n_cols":2,"rows_kept":24,"flags":["formulas_cached_only"]}
["Additional Table 2. Newly formed Ng peptides in plasma incubated with recombinant full-length Ng"]
[]
["Confirmed ","Theoretical"]
["sequence","mass (Da)"]
["24-67a",4223.28]
["33-75a,b",4081.18]
["39-65a",2599.4]
["39-67a",2769.5]
["39-75",3378.8]
["40-68a",2868.58]
["43-65",2203.24]
["43-75",2982.64]
["44-65a,b",2047.14]
["44-67",2217.25]
["44-75",2826.54]
["45-75",2698.45]
["46-75",2570.35]
["48-75",2329.17]
[]
["Plasma samples were depleted of native Ng by three consecutive immunoprecipitations before full-length recombinant Ng (1000 pg/mL) was added to samples followed by 24 h incubation at RT."]
[" After the incubation the samples were analyzed by HI-MS to screen for newly formed Ng peptides. All peptides had a mass deviation < 40 ppm. "]
[]
["a Peptide have not been confirmed by MS/MS, but sequence matches the epitopes of Ng2 and Ng3."]
["b Peptide have been confirmed by MS/MS in CSF"]